We read with great interest the study by Yu et al. 1 titled “Treatment-Specific Clinical and Urinary Biomarker Signatures Associated With Response to Intravesical Botulinum Toxin A and Platelet-Rich Plasma in Bladder Pain Syndrome” published in LUTS: Lower Urinary Tract Syndrome. The authors deserve appreciation for an innovative and clinically relevant approach to predicting treatment response in bladder pain syndrome by integrating clinical characteristics, urodynamic parameters, and urinary biomarkers into treatment-specific models. Their work addresses the critical challenge of disease heterogeneity in IC/BPS and for advancing the concept of phenotype-guided therapy, which represents a promising direction in functional urology. However, despite these noteworthy contributions, several additional limitations warrant consideration. First, there's lack of calibration assessment that limits the understanding of how well predicted probabilities match the actual outcomes, potentially misleading the clinical utility. For Example, Van Calster et al. 2 emphasized that model performance must include both discrimination and calibration, not just AUC. They recommended assessing calibration using plots, calibration slope/intercept, and brier score to ensure that predicted probabilities match the actual outcomes. Second, limited availability of specialized biomarker assays, such as cytokine panels, restricts their use in routine clinical settings. This limits real-world applicability and hinders the translation of findings into broader clinical practice. For example, Hameed et al. 3 emphasized that biomarker-driven and data-intensive models in urology are still in early stages and lack widespread clinical applicability due to cost, complexity, and limited validation. They noted that translation into routine clinical practice remains a major challenge despite promising predictive performance. Third, the study relies on subjective outcome measures (GRA), which are susceptible to recall bias and placebo effects. For instance, Ginkel et al. 4 stated that the patient-reported outcomes in IC/BPS may not accurately reflect true physiological improvement and should be complemented with objective measures. Fourth, heterogeneity in follow-up duration between treatment groups may introduce temporal bias and affect the comparability of outcomes. Differences in follow-up periods can result in inconsistent assessment of treatment effects, as responses may vary over time. For instance, Jhang et al. 5 demonstrated that variations in follow-up timing can significantly influence the evaluation of treatment response in IC/BPS, potentially leading to inaccurate estimates of efficacy and limiting the reliability of comparisons between groups. Thus, future studies should emphasize proper assessment of model calibration using metrics such as calibration plots and Brier scores. They should also improve clinical applicability by prioritizing accessible and cost-effective biomarkers that can be implemented in routine practice. In addition, incorporating both subjective and objective outcome measures is important for a reliable assessment of treatment response. Also, standardizing follow-up duration across studies would help reduce temporal bias and improve comparability of findings. In conclusion, while this study provides useful and clinically relevant insights into predicting treatment response in IC/BPS, several methodological limitations may still affect its broader applicability. Addressing calibration, biomarker feasibility, outcome assessment, and follow-up consistency will be essential to improve the overall reliability and clinical utility of future predictive models. All the authors meet the ICMJE authorship criteria and have made significant and equal contributions to this manuscript. All authors approved the final version and agree to be accountable for all aspects of the work, ensuring the accuracy and integrity of the data and interpretation. All authors have read and approved the final version of the manuscript. They took complete responsibility for the data's integrity and the data analysis's accuracy. The authors have nothing to report. Artificial intelligence (AI) tools, specifically OpenAI's ChatGPT (GPT-4), were used to assist in the drafting and editing of this manuscript. These tools were employed solely to support language refinement, grammar correction, and structural clarity. No AI-generated content was used to replace or simulate original intellectual contributions, data interpretation, critical analysis, or conceptual development. All substantive content reflects the authors' own work and interpretation. The authors have reviewed and verified all AI-assisted text to ensure accuracy and integrity in accordance with the journal's authorship and ethical standards. The authors have nothing to report. The authors affirm that this manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and if relevant, registered) have been explained. The authors have nothing to report. The authors declare no conflicts of interest. Data sharing does not apply to this article as no datasets were generated during the current study; all data were sourced from published literature.
Tahir et al. (Thu,) studied this question.